Healthcare entity
Eli Lilly is the most frequent co-covered peer, appearing in 4 of the 4 tracked stories. The clearest coverage concentration is market-trends: 3 of 4 stories, with the rest divided among 1 other category. They are less corroborated than the beat average, carrying 2 original sources each against 3.3 for the same window.
Last mentioned: Jun 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Eli Lilly is the most frequent co-covered peer, appearing in 4 of the 4 tracked stories. The clearest coverage concentration is market-trends: 3 of 4 stories, with the rest divided among 1 other category. They are less corroborated than the beat average, carrying 2 original sources each against 3.3 for the same window. The 122-day window averages about 0.2 stories each week. Their average consequence score of 6.8 runs above the beat's 6 for that window. We currently track 4 Healthcare stories that mention Retatrutide, published between February 24, 2026 and June 25, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 689 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Retatrutide. Shared-story counts are live from our verified record — not editorial picks.
Regulatory Submissions
Expected window for the first triple-agonist drug applications to the FDA.
STAT News publishes exposé
Citing three anonymous sources, STAT reports the compassionate use approval and notes that top health officials took an unusual interest, prompting speculation the patient was 'well connected.' The outlet asked the White House about Trump's possible involvement due to demographic overlap.
White House denial
Same day, White House spokesman Kush Desai denies on X that the application was for President Trump, with other officials calling the reporting false. They do not confirm the patient's identity.
Compassionate use request submitted
A senior NIH clinician seeks FDA and Eli Lilly permission for a 79-year-old man to receive retatrutide to treat refractory obesity, obstructive sleep apnea, and pulmonary hypertension.
Novo Triple-G Phase 2
Novo Nordisk reports nearly 20% weight loss at 26 weeks.
Phase 3 Expansion
Anticipated start of Novo Nordisk's pivotal late-stage clinical program.
Lilly Retatrutide Phase 2
Eli Lilly releases data showing 17.5% weight loss at 24 weeks.
The White House denied that President Trump is the 79-year-old patient granted compassionate use of Lilly’s investigational weight-loss drug retatrutide, intensifying scrutiny over equity and transparency in the FDA’s expanded access program for experimental obesity treatments.
Source: Josh Marcus (gb) · Kevin Frey (us)
RBC Capital reaffirms Eli Lilly’s Retatrutide as a critical future growth engine, despite recent mixed clinical trial data. The triple-agonist therapy is expected to redefine the weight-loss market by offering superior efficacy compared to existing dual-agonist treatments.
Source: insidermonkey.com · finance.yahoo.com
Eli Lilly's triple-agonist retatrutide achieved a 1.9% reduction in blood sugar levels in its first Phase 3 diabetes trial, a result that matches or slightly trails the performance of its own blockbuster Mounjaro. While the glucose-lowering data is robust, the market's primary interest remains focused on the drug's potential for industry-leading weight loss and metabolic benefits.
Source: Endpoints News · Endpoints News
Novo Nordisk's midstage trial for its 'triple-G' agonist demonstrated nearly 20% weight loss in patients after 26 weeks, positioning it as a potent competitor to Eli Lilly’s retatrutide. While the efficacy data appears slightly superior to Lilly's midstage results, Novo remains behind in the clinical timeline, likely reaching the market second.
Source: Endpoints News · Endpoints News
Retatrutide is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
